Veltio Pharma Secures 8.5 Million SEK Funding for Innovative Drug Treatments

Veltio Pharma AB recently closed a significant investment round, raising 8.5 million SEK. This capital injection marks a crucial step for the company.

Expanding Research to Accelerate Drug Development

With the new funding, Veltio Pharma plans to broaden its research activities.

The investment will allow Veltio Pharma to:

• Increase the number of drug candidates under investigation

• Employ advanced technologies for formulation testing

• Collaborate with research institutions to validate new approaches

• Scale-up production for wider availability

The company’s Chairman of the Board, Daniel Bergström, emphasized the importance of this milestone: “This funding is a key milestone, enabling us to transform promising drug candidates into effective treatments. We appreciate our investors’ trust and support.” This statement reflects the confidence in the company’s path forward.